Copanlisib Lymphoma Data Updated as FDA Considers Approval

June 17, 2017 – Copanlisib showed an objective response rate (ORR) of 59.2% (95% CI, 50.6%-67.3%) without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma, according to findings from the pivotal CHRONOS-1 study presented at the 2017 International Conference on Malignant Lymphoma (ICML) biennial meeting in Lugano, Switzerland. A cohort of 142 patients with … (leggi tutto)